R. Orsenigo

500 total citations
22 papers, 244 citations indexed

About

R. Orsenigo is a scholar working on Hepatology, Immunology and Surgery. According to data from OpenAlex, R. Orsenigo has authored 22 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hepatology, 7 papers in Immunology and 5 papers in Surgery. Recurrent topics in R. Orsenigo's work include Psoriasis: Treatment and Pathogenesis (5 papers), Liver Disease Diagnosis and Treatment (4 papers) and Dermatology and Skin Diseases (4 papers). R. Orsenigo is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (5 papers), Liver Disease Diagnosis and Treatment (4 papers) and Dermatology and Skin Diseases (4 papers). R. Orsenigo collaborates with scholars based in Italy, Switzerland and Germany. R. Orsenigo's co-authors include Michael Rissler, Christian Sieder, Ulrich Mrowietz, A. David Burden, H. Bachelez, Jacek C. Szepietowski, L. Puig, Kristian Reich, J.‐P. Lacour and C. Paul and has published in prestigious journals such as Journal of Hepatology, Journal of the American Academy of Dermatology and American Journal of Transplantation.

In The Last Decade

R. Orsenigo

22 papers receiving 238 citations

Peers

R. Orsenigo

IMMUN

DERMA

EPIDE

PFM

HEPAT

Yu-Huei Huang Taiwan

Ting‐Shun Wang Taiwan

Pattarawat Thantiworasit Thailand

Toshihiro Ito Japan

Amylynne Frankel United States

Gabriel Villada United States

Chiara Franchi Italy

Annie Gardner United States

Anne-Karine Lapointe Switzerland

V Fonollosa Spain

Yu-Huei Huang Taiwan

R. Orsenigo

123 ×0.9

IMMUN

89 ×0.9

DERMA

68 ×1.4

EPIDE

87 ×2.1

PFM

37 ×1.0

HEPAT

Citations per year, relative to R. Orsenigo R. Orsenigo (= 1×) peers Yu-Huei Huang

Countries citing papers authored by R. Orsenigo

Since Specialization

Citations

This map shows the geographic impact of R. Orsenigo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Orsenigo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Orsenigo more than expected).

Fields of papers citing papers by R. Orsenigo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Orsenigo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Orsenigo. The network helps show where R. Orsenigo may publish in the future.

Co-authorship network of co-authors of R. Orsenigo

This figure shows the co-authorship network connecting the top 25 collaborators of R. Orsenigo. A scholar is included among the top collaborators of R. Orsenigo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Orsenigo. R. Orsenigo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stinco, Giuseppe, R. Tiberio, Francesca Prignano, et al.. (2020). Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study. Journal of Dermatological Treatment. 33(1). 401–407. 7 indexed citations

Augustin, Matthias, E. Daudén, Ulrich Mrowietz, et al.. (2020). Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population. Journal of the European Academy of Dermatology and Venereology. 34(11). 2548–2556. 9 indexed citations

Augustin, Matthias, E. Daudén, Ulrich Mrowietz, et al.. (2020). Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. Journal of the European Academy of Dermatology and Venereology. 35(2). 431–440. 18 indexed citations

Mrowietz, Ulrich, H. Bachelez, A. David Burden, et al.. (2019). Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. Journal of the American Academy of Dermatology. 80(5). 1344–1352. 81 indexed citations

Orsenigo, R., et al.. (2015). Glucose abnormalities in Asian patients with chronic hepatitis C. Drug Design Development and Therapy. 9. 6009–6009. 4 indexed citations

Levy, Gary, F. G. Villamil, Frank Nevens, et al.. (2014). REFINE: A Randomized Trial Comparing Cyclosporine A and Tacrolimus on Fibrosis After Liver Transplantation for Hepatitis C. American Journal of Transplantation. 14(3). 635–646. 13 indexed citations

Buti, Marı́a, Robert Flisiak, Jia‐Horng Kao, et al.. (2014). Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon‐based therapy: FUNDAMENTAL, a Phase II trial. Journal of Viral Hepatitis. 22(7). 596–606. 19 indexed citations

Griffel, Louis, W. Bao, R. Orsenigo, et al.. (2013). 821 INTERFERON (IFN)-FREE ALISPORIVIR (ALV) HAS A BETTER OVERALL SAFETY PROFILE COMPARED TO IFN-CONTAINING TREATMENT: A POOLED ANALYSIS OF THE ALV DEVELOPMENT PROGRAM. Journal of Hepatology. 58. S336–S337. 10 indexed citations

Buti, Marı́a, Robert Flisiak, J. Rasenack, et al.. (2013). 1421 ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS). Journal of Hepatology. 58. S572–S572. 2 indexed citations

10.

Perego, Carla, D. Lattuada, Stefano Gatti, et al.. (1998). Study of the immunosuppressive effect of SMS 201-995 and its synergic action with FK 506. Transplantation Proceedings. 30(5). 2182–2184. 1 indexed citations

11.

Perego, Carla, D. Lattuada, Stefano Gatti, et al.. (1998). Evidence that SMS 201-995 enhances the immunosuppressive effect of FK506. International Journal of Immunopharmacology. 20(9). 479–490. 8 indexed citations

12.

Caniatti, M., Luca Crippa, Anna Maria Giusti, et al.. (1998). Cilia‐Associated Respiratory (CAR) Bacillus Infection In Conventionally Reared Rabbits. Journal of Veterinary Medicine Series B. 45(1-10). 363–371. 4 indexed citations

13.

Rossi, G., Stefano Gatti, P. Reggiani, et al.. (1996). Results of orthotopic liver-small bowel transplantation in the pig using different immunosuppressive regimens.. PubMed. 28(5). 2519–22. 1 indexed citations

14.

Reggiani, P., Stefano Gatti, G. Rossi, et al.. (1996). Oral administration of FK 506 in a swine model of liver-small bowel allotransplantation.. PubMed. 28(5). 2587–8. 1 indexed citations

15.

Perego, Carla, O. Marelli, G. Rossi, et al.. (1996). Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens.. PubMed. 28(5). 2471–3. 1 indexed citations

16.

Gridelli, Bruno, Stefano Gatti, P. Andreani, et al.. (1996). Xenogeneic orthotopic liver transplantation from sheep to pig: delay of rejection by FUT 175 Infusion.. PubMed. 28(2). 784–7. 6 indexed citations

17.

Grilli, G., et al.. (1994). Microbiological investigation on frozen rabbit semen. 4 indexed citations

18.

Reggiani, P., R. Orsenigo, Stefano Gatti, et al.. (1994). Conversion to rescue therapy with FK 506: data from eight liver transplant patients.. PubMed. 26(6). 3597–8. 3 indexed citations

19.

Campanati, Loraine, E. Arosio, Stefano Gatti, et al.. (1994). Hepatocyte injection in Gunn rats' thymus and spleen.. PubMed. 26(6). 3443–5. 2 indexed citations

20.

Longhi, Paolo, T. Mussini, R. Orsenigo, & Sandra Rondinini. (1987). Redetermination of the standard potential of the mercuric oxide electrode at temperatures between 283 and 363 K and the solubility product constant of mercuric hydroxide. Journal of Applied Electrochemistry. 17(3). 505–514. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact